*Department of Rehabilitation Medicine, University of Washington, Seattle, WA
†Auxilium Pharmaceuticals, Chesterbrook
§Synchrony Healthcare, West Chester, PA
‡Statistics and Data Corporation, Tempe, AZ
Mark P. Jensen has received consulting fees or research support from Allergan, Irvine, CA, USA, Analgesic Solutions, Natick, MA, USA, Bristol-Myers Squibb, New York, NY, USA, Covidien, Mansfield, MA, USA, Depomed, Newark, CA, USA, Endo Pharmaceuticals, Malvern, PA, USA, Merck, Whitehouse Station, NJ, USA, Pfizer, New York, NY, USA, RTI Health Solutions, Research Triangle Park, NC, USA, Schwartz Biosciences, Raleigh, NC, USA, Smith & Nephew, Andover, MA, USA and Zars Pharma, Salt Lake City, UT, USA, and Zogenix, San Diego, CA, USA within the past 36 months. Xiaojun Hu, Susan L. Potts, and Errol M. Gould were employees of Endo Pharmaceuticals, Malvern, PA, USA, when the original paper this commentary is based on was submitted for publication. The authors declare no conflict of interest.
Reprints: Mark P. Jensen, PhD, Department of Rehabilitation Medicine, University of Washington, Box 359612, Harborview Medical Center, 325 Ninth Avenue, Seattle, WA 98104 (e-mail: email@example.com).